- Home
- COYA vs WHWK Comparison
COYA vs WHWK Comparison
Compare COYA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- WHWK
- Stock Information
- Founded
- COYA 2020
- WHWK 2007
- Country
- COYA United States
- WHWK United States
- Employees
- COYA N/A
- WHWK N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- WHWK Health Care
- Exchange
- COYA Nasdaq
- WHWK Nasdaq
- Market Cap
- COYA 107.0M
- WHWK 95.2M
- IPO Year
- COYA 2022
- WHWK N/A
- Fundamental
- Price
- COYA $6.00
- WHWK $2.22
- Analyst Decision
- COYA Strong Buy
- WHWK
- Analyst Count
- COYA 5
- WHWK 0
- Target Price
- COYA $16.20
- WHWK N/A
- AVG Volume (30 Days)
- COYA 299.7K
- WHWK 5.2M
- Earning Date
- COYA 11-06-2025
- WHWK 11-05-2025
- Dividend Yield
- COYA N/A
- WHWK N/A
- EPS Growth
- COYA N/A
- WHWK N/A
- EPS
- COYA N/A
- WHWK N/A
- Revenue
- COYA $423,452.00
- WHWK $21,596,000.00
- Revenue This Year
- COYA $40.80
- WHWK N/A
- Revenue Next Year
- COYA N/A
- WHWK N/A
- P/E Ratio
- COYA N/A
- WHWK N/A
- Revenue Growth
- COYA N/A
- WHWK N/A
- 52 Week Low
- COYA $4.65
- WHWK $1.39
- 52 Week High
- COYA $8.29
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- COYA 45.68
- WHWK 49.63
- Support Level
- COYA $6.07
- WHWK $2.28
- Resistance Level
- COYA $6.50
- WHWK $2.49
- Average True Range (ATR)
- COYA 0.51
- WHWK 0.34
- MACD
- COYA -0.07
- WHWK -0.02
- Stochastic Oscillator
- COYA 3.13
- WHWK 13.41
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.